Results 61 to 70 of about 2,201,777 (199)

PIM1 kinase promotes EMT-associated osimertinib resistance via regulating GSK3β signaling pathway in EGFR-mutant non-small cell lung cancer

Cell Death and Disease
Acquired resistance is inevitable in the treatment of non-small cell lung cancer (NSCLC) with osimertinib, and one of the primary mechanisms responsible for this resistance is the epithelial-mesenchymal transition (EMT).
Jing Zhou, Xinyue Wang, Zhaona Li, Fan Wang, Lianjing Cao, Xiuqiong Chen, Dingzhi Huang, Richeng Jiang   +7 more
doaj   +1 more source

DLST Succinylation‐Mediated Mitochondrial Metabolic Remodeling and Cuproptosis Resistance Promote Malignant Progression of Lung Adenocarcinoma

Advanced Science, EarlyView.
The DLST K409 succinylation mediated by CPT1A promotes OXPHOS and redox homeostasis through regulating enzyme activity, thereby promoting the malignant progression of LUAD. Notably, the succinylation of DLST can enhance the cuproptosis resistance by inhibiting its lipoylation.
Xuanxuan Li, Peijun Zhou, Xingzhi Peng, Qixin Liu, Wenhui Zeng, Rui Wang, Liangfang Shen, Jinwu Peng, Qin Zhou, Lifang Yang   +9 more
wiley   +1 more source

Inhibition of PGC1β-dependent mitochondrial biogenesis enhances EGFR-targeted therapy in lung cancer

EMBO Molecular Medicine
Third-generation EGFR tyrosine kinase inhibitors (EGFR-TKIs), including osimertinib, show robust clinical efficacy in EGFR-mutant (EGFRm) non-small cell lung cancer (NSCLC), yet acquired resistance remains inevitable.
Zhen Chen, Dongsheng Wang, Songqing Fan, Qiming Wang, Yong Huang, Pan Du, Shidong Jia, Suresh S Ramalingam, Shi-Yong Sun   +8 more
doaj   +1 more source

Granzyme B PET Imaging Reveals Lgmn+ Macrophage‐Mediated Immune Evasion and Guides Immunotherapy in EGFR‐TKI‐Resistant NSCLC

Advanced Science, EarlyView.
Graphical illustration of 68Ga‐GZB PET/CT imaging reveals immune dynamics post‐EGFR‐TKI resistance in NSCLC; Lgmn+ macrophages‐derived Lgmn‐containing extracellular vesicles inhibit glycolysis, induce CD8+ T cell exhaustion, and targeting Lgmn restores immunotherapy sensitivity.
Dongliang Wang, Wenqin Luo, Qiufang Liu, Wenxuan Tang, Bin Zhu, Jiwei Chen, Qian Zhou, Shuang Tang, Xiaoping Xu, Shaoli Song   +9 more
wiley   +1 more source

Resistance profile of osimertinib in real-world practice.

, 2019
Resistance profile of osimertinib in real-world practice.
Shin-Kyo Yoon (6191396), Dong Kyu Oh (6191390), Woo Sung Kim (91686), Jin Kyung Rho (493775), Chang-Min Choi (493779), Jae Cheol Lee (493780), Won Jun Ji (6191393)   +6 more
core   +1 more source

Efficacy and Tolerability of Osimertinib and Sotorasib Combination Treatment for Osimertinib Resistance Caused by KRAS G12C Mutation:A Report of Two Cases

, 2023
Osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), is currently considered the standard first-line systemic treatment for patients with advanced EGFR-mutated non–small-cell lung cancer (NSCLC ...
van Schaik, Ron H N, van Marion, Ronald, de Jonge, Evert, Uzun, Sevim, Aerts, Joachim G J V, von der Thüsen, Jan H; id_orcid, Dingemans, Anne-Marie C; id_orcid, Paats, Marthe S; id_orcid, Ernst, Sophie M, Atmodimedjo, Peggy N, Dubbink, Hendrikus J; id_orcid   +10 more
core   +1 more source

Regulatory harmonization: Evolution, globalization and future directions

British Journal of Clinical Pharmacology, EarlyView.
Regulatory harmonization has become an increasingly important and accepted approach to streamline regulatory review processes and expedite access to safe, effective and high‐quality medicines globally. This review explores the evolution and current status of regulatory harmonization, convergence and reliance initiatives.
Orin Chisholm, Elaine Y. L. Blair, Christine Y. Lu   +2 more
wiley   +1 more source

Autophagy determines osimertinib resistance through regulation of stem cell-like properties in EGFR-mutant lung cancer

, 2018
Drug resistance to Osimertinib, a 3rd-generation EGFR-TKI is inevitable. Autophagy plays a contradictory role in resistance of 1stand 2ndgeneration EGFR-TKI, and its significance in osimertinib resistance is much less clear.
Kejun Zhang, Chen Hu, Mingxia Feng, Yubo Wang, Conghua Lu, Junyi Ye, Dadong Zhang, Caiyu Lin, Lin Jiao, Li Li, Yong He   +10 more
core   +1 more source

MET Alterations Are Associated With Osimertinib Resistance in EGFR Mutant Lung Cancers, a Meta-Analysis [PDF]

, 2023
Osimertinib is a third-generation tyrosine kinase inhibitor (TKI) that has been used to treat EGFR mutant lung cancers, especially those with EGFR T790M mutation.
Viola, Marissa, Le, Annie, Wang, Jun
core   +1 more source

The potential impact of H1 antihistamines on clinical outcomes in NSCLC patients undergoing EGFR‐TKIs treatment

British Journal of Clinical Pharmacology, EarlyView.
Background Epidermal growth factor receptor–tyrosine kinase inhibitors (EGFR‐TKIs) have substantially improved outcomes in non‐small cell lung cancer (NSCLC); however, the development of treatment resistance remains a major clinical challenge. This study examines the association between concomitant prescriptions of H1‐antihistamines (H1AHs) and ...
Van Thuan Nguyen, Ngoc Hoang Le, Nhu Quynh Phan, Toan Trung Duong, Le Thi Anh Thu, Hsuan‐Chia Yang, Chih‐Wei Huang, Min‐Huei Hsu, Jason C. Hsu, Chien‐Tien Su, Phung‐Anh Nguyen   +10 more
wiley   +1 more source